ChiCTR2000038464 版本V1.5 版本创建时间2020/12/24 18:28:49 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2000038464 

最近更新日期:

Date of Last Refreshed on:

2020-12-24 18:27:16 

注册时间:

Date of Registration:

2020-09-23 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

周围神经阻滞在预防乳腺癌术后慢性疼痛中的作用

Public title:

Effects of regional anesthesia on chronic postsurgical pain after breast cancer surgery

注册题目简写:

English Acronym:

研究课题的正式科学名称:

多模式镇痛背景下周围神经阻滞在预防乳腺癌术后慢性疼痛中的作用

Scientific title:

Effects of regional anesthesia in a multimodal analgesia setting on chronic postsurgical pain after breast cancer surgery

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

辛玲 

研究负责人:

辛玲 

Applicant:

Xin Ling 

Study leader:

Xin Ling 

申请注册联系人电话:

Applicant telephone:

+86 13810096289

研究负责人电话:

Study leader's telephone:

+86 13810096289

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

sirius1984@sina.com

研究负责人电子邮件:

Study leader's E-mail:

sirius1984@sina.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市西城区西直门南大街11号

研究负责人通讯地址:

北京市西城区西直门南大街11号

Applicant address:

11 Xizhimen Street South, Xicheng District, Beijing, China

Study leader's address:

11 Xizhimen Street South, Xicheng District, Beijing, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

北京大学人民医院

Applicant's institution:

Peking University People's Hospital

研究负责人所在单位:

北京大学人民医院

Affiliation of the Leader:

Peking University People's Hospital

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2020PHB222-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

北京大学人民医院伦理审查委员会

Name of the ethic committee:

Institutional Review Board of Peking University People's Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2020-09-01 00:00:00

伦理委员会联系人:

母双

Contact Name of the ethic committee:

Mu Shuang

伦理委员会联系地址:

北京市西城区西直门南大街11号

Contact Address of the ethic committee:

11 Xizhimen Street South, Xicheng District, Beijing, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

北京大学人民医院

Primary sponsor:

Peking University People's Hospital

研究实施负责(组长)单位地址:

北京市西城区西直门南大街11号

Primary sponsor's address:

11 Xizhimen Street South, Xicheng District, Beijing, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

北京大学人民医院

具体地址:

西城区西直门南大街11号

Institution
hospital:

Peking University People's Hospital

Address:

11 Xizhimen Street South, Xicheng District

经费或物资来源:

自筹

Source(s) of funding:

Self-fund

Target disease:

Chronic pain

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

乳腺癌患者常遗留术后慢性疼痛。周围神经阻滞是预防术后急性疼痛的常用技术,但对慢性疼痛的影响尚存在争议。本研究拟通过回顾性分析患者的临床资料,对入组患者进行电话随访,比较周围神经阻滞患者与非神经阻滞患者CPSP的发生率,探讨周围神经阻滞对乳腺癌术后患者慢性疼痛的影响。  

Objectives of Study:

Chronic postsurgical pain (CPSP) is common following breast cancer surgery (BCS). Regional anesthesia (RA) is established form of perioperative acute pain control while existing evidence remains conflicting on its influence on CPSP. In this ambispective cohort study, we evaluated the long-term effects of RA techniques in preventing CPSP after more than one year in BCS patients.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

女性;
ASA分级I到III级;
麻醉方式为全麻或全麻复合周围神经阻滞。

Inclusion criteria

1. Female patients;
2. Subjects with ASA grade I to III;
3. General anesthesia or general anesthesia combined with peripheral nerve block.

排除标准:

术前合并精神心理疾病;
双侧乳腺癌手术;
乳腺良性肿瘤;
转移性乳腺癌;
合并其他恶性肿瘤;
既往乳腺癌手术史;
乳房重建术;
合并其他慢性疼痛并服用止痛药物。

Exclusion criteria:

1. Patients with mental and psychological diseases before operation;
2. Patients with bilateral breast cancer surgery;
3. Patients with benign breast tumor;
4. Patients with metastatic breast cancer;
5. Patients with other malignant tumors;
6. Patients with previous breast cancer surgery history;
7. Patients with breast reconstruction;
8. Patients with other chronic pain and taking analgesic drugs.

研究实施时间:

Study execute time:

From 2020-10-01 00:00:00 To 2022-09-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2020-10-01 00:00:00 To 2022-09-30 00:00:00  

干预措施:

Interventions:

组别:

Group 1

样本量:

185

Group:

Group 1

Sample size:

干预措施:

神经阻滞+全麻

干预措施代码:

Intervention:

regional anesthesia+general anesthesia

Intervention code:

组别:

Group 2

样本量:

185

Group:

Group 2

Sample size:

干预措施:

全麻

干预措施代码:

Intervention:

general anesthesia

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China 

Province:

Beijing 

City:

 

单位(医院):

北京大学人民医院 

单位级别:

三级 

Institution
hospital:

Peking University People's Hospital

Level of the institution:

Tertiary

测量指标:

Outcomes:

指标中文名:

慢性疼痛发生率

指标类型:

主要指标

Outcome:

incidence of CPSP

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

神经病理性痛发生率

指标类型:

次要指标

Outcome:

incidence of NP

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

N/A

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 0 years
最大 Max age 99 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

未使用

Randomization Procedure (please state who generates the random number sequence and by what method):

Not use

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

ResMan 临床试验公共管理平台, http://www.medresman.org.cn

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

ResMan, http://www.medresman.org.cn.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

ResMan

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

ResMan

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2020-09-23 00:46:54